RxDoctor Payments Data

Stephen Tanner, MD

Internal Medicine · Temple, TXNPI 1700268059

Payments from drug & device makers

$466in general payments, 2019–2025

Across 15 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Veloxis Pharmaceuticals, Inc.$146
  • AstraZeneca$95
  • Vifor Pharma, Inc.$56
  • Amgen$53
  • Astellas Pharma US Inc$37
  • Novartis$25
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$20444%
  • Education$26156%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$466 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$129,990
Medicare patients
388
Services billed
1,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex40$44,656
JardianceEmpagliflozin24$36,642
KerendiaFinerenone26$24,750
FarxigaDapagliflozin Propanediol15$19,426
Tamsulosin Hcl83$2,361
Lisinopril171$1,747
Eplerenone15$1,701
Losartan Potassium111$1,606
Spironolactone74$1,278
Carvedilol74$1,273
Amlodipine Besylate159$1,246
Torsemide41$1,128
Calcium Acetate23$1,046
Hydralazine Hcl33$783
Potassium Chloride41$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$20$24,75026 claims
AstraZenecaFarxiga$95$19,42615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →